United States News Todas as matérias

AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.

Meta Platforms (NASDAQ:META) and EssilorLuxottica are in discussions to double their production capacity for AI-powered smart glasses to 20 million units annually by the end of 2025, according to people familiar with the matter.

Polygon Labs announced the acquisition of Coinme and Sequence in a combined deal valued at $250 million, marking a strategic shift towards becoming a regulated payments-focused company.

Delta Air Lines (NYSE:DAL) signaled a major shift in its widebody strategy Tuesday, placing its first direct order for the Boeing 787 Dreamliner to anchor its international expansion through the next decade.

Sono-Tek Corporation (NASDAQ:SOTK) reported a significant jump in profitability for its third fiscal quarter, as a strategic pivot toward complex, high-value coating systems offset a slight dip in overall revenue.

The U.S. Consumer Price Index (CPI) rose at an annual rate of 2.7% in December 2025, matching the previous month’s pace and signaling that the long-awaited "last mile" to the Federal Reserve’s 2% target remains elusive.

ImmunityBio (NASDAQ:IBRX) announced positive results Tuesday from its ANKTIVA® clinical program, signaling a potential paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC) for patients who have exhausted standard-of-care options.

Franklin Templeton has updated two long-standing institutional money market funds to support stablecoin reserves and onchain cash activity without creating new crypto-native products.

The Baldwin Group (NASDAQ:BWIN) announced Tuesday the completion of its acquisition of Creisoft, better known as Obie, a Chicago-based insurtech pioneer.

AudioEye (NASDAQ:AEYE) announced Tuesday its 40th consecutive period of record revenue, signaling that the global push for digital accessibility continues to fuel the company’s expansion.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.

U.S. Bancorp (NYSE:USB) agreed to acquire financial services firm BTIG in a deal valued at as much as $1 billion, a strategic move by the fifth-largest U.S. bank to aggressively expand its footprint in investment banking and institutional trading.

BNY (NYSE:BNY) reported fourth-quarter 2025 results that surpassed Wall Street’s expectations, fueled by a surge in fee-based income and a record expansion of its custody empire.

Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.

Concentrix Corporation (NASDAQ:CNXC) reported fourth-quarter and full-year 2025 results that beat its own revenue targets, even as a massive non-cash impairment charge forced the company into a GAAP operating loss.

NeuroPace (NASDAQ:NPCE) crossed a major financial threshold in 2025, reporting preliminary full-year revenue of approximately $100 million as its brain-responsive neurostimulation technology gains traction as a standard of care for drug-resistant epilepsy.

Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.

JPMorgan Chase & Co. (NYSE:JPM) kicked off the 2026 earnings season on Tuesday with a complex set of results that highlighted a growing divide between its "Main Street" lending and "Wall Street" trading arms.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.

Sight Sciences (NASDAQ:SGHT), a leader in interventional eyecare technologies, released preliminary fourth-quarter 2025 results on Jan. 13, showing a return to growth driven by its interventional dry eye business.

Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.

Armata Pharmaceuticals (NYSE:ARMP) is poised to become the first company to advance a bacteriophage candidate into a Phase 3 clinical trial, following a positive End-of-Phase 2 (EOP2) response from the U.S. Food and Drug Administration (FDA).

AerCap Holdings N.V. (NYSE:AER), the world’s largest aircraft lessor, has reached a significant agreement with Virgin Atlantic to finance six new Airbus A330-900 aircraft.

Cardinal Health (NYSE:CAH) raised its fiscal year 2026 earnings outlook Tuesday, citing rapid acceleration in its specialty pharmaceutical business and a successful navigating of federal drug pricing changes.